
Opinion|Videos|January 2, 2025
Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
Author(s)Hadar Lev-Tov, MD
Panelist discusses how the misalignment between Hurley stages and patient burden in hidradenitis suppurativa (HS) creates diagnostic and treatment challenges. Current Hurley staging inadequately captures the full patient experience, potentially leading to suboptimal treatment approaches. Standardized clinical training and assessment tools that incorporate both objective staging and subjective patient-reported outcomes could help bridge this gap, enabling more personalized and comprehensive HS management.
Advertisement
Episodes in this series

Advertisement
Related to this article

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes
3
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
4
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
5



